北京若生智能科技有限公司
Drug Database
PA

pantoprazole

✓ Approved

Nanodaru · ATP4A · 小分子

什么是 pantoprazole？

pantoprazole 是一种小分子，由Nanodaru研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

公司Nanodaru
药物类别小分子
分子靶点ATP4A
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Nanodaru

作用机制

分子靶点

pantoprazole 作用于 1 个分子靶点：

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pantoprazole 针对 4 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastrinoma✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

相关研究文献

PubMedFrontiers in cellular and infection microbiology2026-10-27

Effect of a potassium-competitive acid blocker on the gut microbiota in patients undergoing percutaneous coronary intervention: a randomized pilot study.

Lee Sang Hoon SH, Na Seong-In SI, Park Sung Chul SC, Cho Byung Ryul BR et al.

Proton pump inhibitors (PPIs) are routinely used in patients undergoing percutaneous coronary intervention (PCI) to prevent gastrointestinal bleeding associated with dual-antiplatelet therapy (DAPT). However, long-term PPI use has been linked to gut microbiota dysbiosis. Tegoprazan, a potassium-competitive acid blocker (P-CAB), may exert distinct effects on the gut microbiome. This study compared the longitudinal effects of tegoprazan and pantoprazole on gut microbiota composition in patients with angina undergoing PCI. This prospective, randomized, controlled pilot study randomized 38 patients 1:1:1 to tegoprazan 50 mg once daily, pantoprazole 40 mg once daily, or no acid-suppressive therapy for 24 weeks. Five participants did not provide baseline fecal samples, and nine discontinued participation before week 24. Thus, 24 participants with paired baseline and week-24 fecal samples were included in the final analysis. Fecal samples were analyzed using 16S rRNA gene sequencing. No drug-related adverse events or gastrointestinal bleeding occurred in any group. Observed amplicon sequence variant (ASV) richness was significantly higher at week 24 than at baseline in the overall cohort (p = 0.003) and P-CAB group (p = 0.016), whereas the Shannon index showed no significant changes. Paired PERMANOVA with permutations restricted by patient ID revealed significant differences in Bray-Curtis beta diversity between baseline and week 24 in the P-CAB group (R² = 0.070, p = 0.031) and PPI group (R² = 0.059, p = 0.008), but not in the no acid-suppressive therapy group (R² = 0.021, p = 0.691). In the formal cross-arm analysis, the treatment group-by-visit interaction was not significant for Bray-Curtis beta diversity (R² = 0.021, pseudo-F = 0.505, p = 0.270). Although nominal within-arm taxonomic changes were observed, no treatment group-by-visit interaction survived Benjamini-Hochberg correction in ANCOM-BC2. Tegoprazan was well tolerated, with no drug-related adverse events or gastrointestinal bleeding during the 24-week follow-up. Both acid-suppressive treatment groups showed modest longitudinal microbiome changes. The taxon-level findings were exploratory and hypothesis-generating and should not be interpreted as definitive evidence of treatment-specific differential effects. Larger, adequately powered studies are required to confirm these observations.

PMID 42935576
阅读全文 →
PubMedBiomedicines2026-10-27

Prevalence and Patterns of Self-Reported Proton Pump Inhibitor Use Among Internal Medicine Outpatients: A Cross-Sectional Study from Türkiye.

Uçar Ayşenur A, Erdevir Mehmet M, Arslan Felemez F

Background/Objectives: Proton pump inhibitors (PPIs) are widely used, but real-world utilisation data from internal medicine settings remain limited. We estimated the screening-period prevalence of self-reported current PPI use among attendees of two internal medicine outpatient clinics and described treatment patterns among current users. Methods: In this single-centre cross-sectional survey in Adana, Türkiye (August 2025-January 2026), 977 consecutively screened adult outpatients were asked about current PPI use; 178 reported current use, and 149 of them (83.7%) completed an investigator-administered questionnaire. Wilson 95% confidence intervals (CIs) were calculated for the prevalence and three prespecified proportions; exploratory ≤6-versus > 6-month comparisons used exact tests with Holm adjustment. Results: Current use was reported by 178/977 outpatients (18.2%; 95% CI 15.9-20.8%). Among users (mean age 57.5 ± 13.6 years; 61.1% women), median reported duration was 54 months (interquartile range 18-84); 86.6% reported use for >6 months and 34.2% for >5 years. Pantoprazole was most common (31.5%). Gastroprotection during non-steroidal anti-inflammatory drug (NSAID) or antithrombotic therapy (45.0%) and dyspepsia (35.6%) were the leading reasons; 80.6% of those citing gastroprotection reported current NSAID or antithrombotic use. Ongoing upper-gastrointestinal symptoms were reported by 77.9% (59.7% of those citing gastroprotection; 100.0% of those citing reflux). Conclusions: Nearly one in five screened outpatients reported current PPI use, and reported exposure was predominantly prolonged. Ongoing symptoms and prolonged use without a documented indication are signals that should prompt structured, individualised medication review.

PMID 42939998
阅读全文 →
PubMedPharmaceuticals (Basel, Switzerland)2026-10-27

Old Drugs, New Targets: Molecular Docking Insights into Repurposing Proton Pump Inhibitors for the TLR4/MD-2, NLRP3, and C5aR1 Axes in Autoimmune Liver Diseases.

Yıldız Mehmet M, Şeker Erdi E, Altınkaya Engin E, Poustforoosh Alireza A et al.

Background/Objectives: Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, may include treatment-resistant cases and therefore require new therapeutic strategies. This in silico study evaluated proton pump inhibitors (PPIs) across three pathophysiologically complementary inflammatory targets relevant to hepatic immune injury: TLR4/MD-2, representing upstream innate immune sensing; NLRP3, representing inflammasome-mediated inflammatory amplification; and C5aR1, representing complement-dependent leukocyte recruitment. Methods: The binding profiles of four PPIs (rabeprazole, lansoprazole, omeprazole, and pantoprazole) were analyzed by molecular docking against TLR4/MD-2 (3FXI), NLRP3 (7VTP and 7PZC), and C5aR1 (6C1R and 5O9H). TAK-242, MCC950, and avacopan were included as target-associated reference ligands solely to provide structural and protocol-specific context. Their docking scores were not used as benchmarks of relative binding affinity, inhibitory potency, or pharmacological efficacy. MM-GBSA binding free energy calculations for the best score in all proteins were performed. Molecular docking and molecular dynamics analyses indicated stable interactions for the best docking score. Results: PPIs showed variable but potentially meaningful docking affinities across the evaluated targets. Rabeprazole produced favorable docking scores within the investigated TLR4/MD-2 (-7.85 kcal/mol) and inactive NLRP3 (-9.10 kcal/mol) binding sites under the present docking protocol. The reference ligands TAK-242 and MCC950 were included only to provide structural and protocol-specific context, and their docking scores were not interpreted as measures of relative pharmacological potency. Among the PPIs, lansoprazole showed the most favorable docking score for the C5aR1 allosteric site (-6.93 kcal/mol). Interaction analyses suggested favorable hydrophobic contacts and substantial spatial occupancy within the investigated binding pockets; however, cross-target docking compatibility may partly reflect nonspecific hydrophobic accommodation rather than genuine polypharmacology, and whether these predicted interactions produce target-specific functional effects requires experimental validation. MM-GBSA analysis supported the predicted stability of the rabeprazole-NLRP3 (7PZC) complex (ΔGbind = -56.97 kcal/mol). Conclusions: These findings prioritize rabeprazole and lansoprazole as PPI scaffolds showing favorable predicted interactions across several inflammation-related target structures within the applied computational framework. These results are hypothesis-generating and do not establish target inhibition, target engagement, or therapeutic efficacy. The results are hypothesis-generating and warrant experimental studies to determine whether these predicted interactions translate into target engagement or modulation of inflammatory signaling in AILDs.

PMID 42943278
阅读全文 →
PubMedRevista espanola de enfermedades digestivas2026-10-26

Partial regression of a refractory gastric ulcer following abdominal radiotherapy during a sofalcone-containing combination regimen.

Guo Zhong-Wei ZW, Zhang Jin-Xuan JX, Li Han-Chuan HC, Chang Xin-Yao XY et al.

Radiation-induced gastric ulcer is uncommon but can be persistent and difficult to heal, particularly in patients receiving ongoing multimodality cancer treatment. We report a 68-year-old man with pancreatic ductal adenocarcinoma who developed a refractory antral ulceration after upper abdominal radiotherapy during intermittent chemotherapy. High-dose pantoprazole, rebamipide, Kangfuxin liquid, and subsequent vonoprazan achieved bleeding control but failed to induce healing. After sofalcone was added, postprandial pain improved substantially, and serial endoscopy showed regression of the ulcer from 2.0×1.8 cm to 0.6×0.8 cm. This case highlights the therapeutic challenge of post-radiation gastric ulceration and supports further study of repair-directed therapy.

PMID 42929252
阅读全文 →
PubMedJournal of xenobiotics2026-10-26

Comparative Reporting Patterns of Rabeprazole and Other Proton Pump Inhibitors in EudraVigilance: A System Organ Class-Level Disproportionality Analysis.

Moleriu Radu Dumitru RD, Cioacă Gabriela Ramona GR, Muntean Călin C, Ilie Adrian-Cosmin AC et al.

Rabeprazole differs from other proton pump inhibitors (PPIs) in its activation and lower dependence on CYP2C19. We compared its System Organ Class (SOC)-level reporting profile with those of esomeprazole, pantoprazole, omeprazole and lansoprazole in EudraVigilance individual case safety reports (ICSRs). Aggregated ICSR counts were retrieved from adrreports.eu (data lock point 4 October 2026). Rabeprazole was compared head-to-head with each comparator using reporting odds ratios (RORs) with 95% confidence intervals across 27 MedDRA SOCs, with Benjamini-Hochberg false discovery rate control over all 108 tests. Bonferroni correction and serious-only analyses were sensitivity analyses; female-only and male-only analyses were exploratory. Of 232,045 ICSRs, 7960 involved rabeprazole. Hepatobiliary disorders were the only SOC reported more often with rabeprazole than with all four comparators (ROR 1.29-1.96); the excess met the Bonferroni threshold and persisted among serious reports (ROR 1.19-1.97) and in both sexes. Skin and subcutaneous tissue disorders were reported more often than with three comparators and, among serious reports, than with all four (ROR 1.14-1.83). Eight SOCs showed consistently lower reporting odds, alongside fewer SOCs per rabeprazole ICSR and a different reporter mix. Rabeprazole showed a consistent hepatobiliary reporting signal within the PPI class, in line with earlier FAERS findings. This is a reporting signal, not a clinical signal: without exposure data, the results describe relative reporting, not incidence, comparative risk or causality, and lower reporting odds do not imply lower clinical risk.

PMID 42931086
阅读全文 →
PubMedPostgraduate medicine2026-10-16

Changes in intravenous pantoprazole utilization following two sequential interventions in a tertiary referral hospital.

Kargar Mona M, Mousavi Saeideh S, Gholami Kheirollah K, Javadi Mohammad Reza MR et al.

Intravenous (IV) pantoprazole is an effective proton pump inhibitor (PPI) with certain evidence-based indications for acid-related disorders. However, many studies demonstrated the considerable inappropriate administration of IV pantoprazole, resulting in adverse drug reactions and a financial burden. Irrational pantoprazole use necessitates educational and regulatory interventions. This study aimed to assess the effects of a hospital-wide program to optimize pantoprazole use in a tertiary‑care, referral, university-affiliated hospital. This study was conducted in three 45-day evaluation phases, before and after two sequential interventions, including the implementation of institutional guidelines with educational sessions and an order entry form (OEF). The use and appropriateness of IV pantoprazole were evaluated in each evaluation phase, and the hospital consumption (DDD/100 Bed-Days) of IV pantoprazole was estimated from 2014 to 2021. The appropriate use of stress ulcer prophylaxis (SUP) in the first-day evaluation of the third phase increased significantly by 7% compared to the first and second evaluation phases (p = 0.03), while other indications remained unchanged. The total number of vials per patient over the 5 days decreased significantly during the three evaluation phases of the study (Coefficient = -0.05, SE = 0.02, p = 0.003). Sequential interventions in our study reduced IV pantoprazole consumption. However, we did not observe a significant improvement in appropriate IV pantoprazole use except for SUP in one of the assessments. Although the reasons behind this should be studied, more comprehensive, continuous, and effective interventions should have been considered to achieve acceptable change.

PMID 42885823
阅读全文 →

注册免费账户还可查看另外 2423 篇文献

免费注册查看全部文献 →

了解更多pantoprazole